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A R T I C L E   I N F O A B S T R A C T 
Genetic and epigenetic alterations significantly contribute to development of human 
cancer. Genotyping tumour tissue in search for these actionable genetic and 
epigenetic changes has become routine practice in oncology. However, sampling 
tumour tissue has significant inherent limitations. It provides only a single snapshot 
in time, prone to selection bias due to intra-tumour heterogeneity, and cannot 
always be performed owing to its invasive nature. Circulating tumour DNA 
(ctDNA) based liquid biopsy provides an effective alternative to invasive tissue 
sampling and have emerged as a minimally invasive, real-time biomarker. Recent 
advancements in DNA sequencing technologies have revealed enormous potential 
of ctDNA to improve tumour detection and stratification. In this review, we 
critically appraise the role of ctDNA as a liquid biopsy for cancer and evaluate the 
role of circulating tumour DNA as a diagnostic, prognostic and predictive 
biomarker. We also highlight some technical challenges and constraints associated 
with circulating DNA analysis. 
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INTRODUCTION 
The advent of personalised medicine has 
revolutionised cancer management. Advancements in 
genomics and transcriptomics have enabled 
identification of gene signatures and targets that can 
be used for diagnostics, prognostics, predictive and 
therapeutic purposes (Gonzalez de Castro et al. 2013). 
Analysis of tumour-linked genetic alterations has 
become routine practice in oncology. Genetic profiling 
of solid tumours requires the sample of the abnormal 
tissue (mass, lesions or tumour) which is usually 
obtained by invasive biopsy (Amalou and Wood 
2012). However, the invasive tissue biopsy is 
associated with significant risks, complications and 
limitations described blow.  
Intra-tumour heterogeneity and tumour evolution 
It has been shown that a tumour consists of a variety 
of sub-clones that harbour different genetic and 
epigenetic alterations, a phenomena termed as intra-
tumour heterogeneity (ITH) (Marusyk et al. 2012; 
Swanton 2012). A study by Gerlinger et al. (2012) 
showed that biopsy samples taken from different 
regions of Renal Cell Carcinoma displayed 
heterogeneous somatic mutations and were not 
detectable in every region of the tumour sequenced. 
Similarly, Bashashati et al. (2013) have observed 
regional diversity in mutations, copy numbers and 
gene expression profiles in primary ovarian cancers 
prior to therapeutic intervention. Therefore, biopsy of 
a small region of tumour might not account for ITH 
and could not accurately characterise distinct 
molecular alterations present within a single tumour.  
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It is also widely accepted that tumour development 
follows a process of Darwinian-like clonal evolution 
(Gerlinger and Swanton 2010; Gerlinger et al. 2012). 
High throughput sequential analysis of tumour 
samples has revealed that ITH evolves temporally 
under selection pressures imposed by the 
microenvironment and/or the cancer therapeutics 
(Anderson et al. 2006; Hunter et al. 2006; Edwards et 
al. 2008). It implies that the historical tissue biopsy 
taken at the time of diagnosis might not effectively 
guide clinical decisions after some passage of time and 
should be supplemented by serial tissue sampling to 
account for new mutations.  
Limitations in tissue processing 
Processing of tumour tissue sample affects the quality 
of DNA obtained. Studies have shown that formalin 
fixation causes DNA denaturation, base alteration and 
production of sequence artefact (Douglas and Rogers 
1998; Oh et al. 2015). Gallegos Ruiz and colleagues 
(2007) have observed mutational artefacts in 
epidermal growth factor receptor (EGFR) gene 
resulting from formalin fixation and paraffin 
embedding of lung tissue sample. Therefore, 
formalin-processed tissue specimens might not 
accurately reflect the genetic alterations present in the 
tumour tissue. The use of fresh frozen tissue for 
processing might overcome these limitations, but it is 
restricted by logistic issues such as availability of 
liquid nitrogen and requirement of specialised 
equipment for processing and storage of frozen tissue 
(Budczies et al. 2011; Oh et al. 2015).      
Associated risks and complications 
Tissue sampling is invasive and is associated with 
significant risks and complications depending on the 
type and site of the biopsy. A systematic review on 
complications of the prostate biopsy by Loeb et al. 
(2013) showed that it is associated with complications 
such as pain, haematuria, haematospermia and 
urinary tract infection. Although most of these 
complications were mild and self-limiting, longer 
hospital stay and serious adverse events were 
reported in patients undergoing surgical biopsy 
(Lebofsky et al. 2015). Additionally, it is speculated 
that certain biopsies are associated with dislocation 
and seeding of malignant cells along the needle track 
leading to local recurrence and/or systemic spread 
(Shyamala et al. 2014).  
Liquid biopsy - a paradigm shift in cancer testing: 
The liquid biopsy is a minimally invasive blood test 
that detects tumour biomarkers (DNA, RNA, protein) 
in the circulation. It has emerged as an effective 
alternative to traditional tumour tissue sampling 
(Karachaliou et al. 2015). Being a simple blood test, it 
can be repeated to account for the changing genomic 
landscape of a tumour to track tumour evolution and 
monitor response to therapy. Additionally, it has the 
potential to interrogate genetic profiles of primary 
and metastatic tumours in the body which overcome 
intra-tumour heterogeneity and sampling bias. One of 
the most promising application of liquid biopsy is cell-
free circulating tumour DNA (ctDNA).    
THE BIOLOGY OF ctDNA 
ctDNA, as the name implies, is the presence of 
tumour-DNA fragments in the circulation that shows 
similar molecular alterations present in the 
corresponding tumour in the body. The presence of 
cell-free nucleic acids in the human blood was first 
reported by Mandel and Metais (1948). It was 
subsequently found that the concentration of cell-free 
DNA is significantly higher in the circulation of cancer 
patients compared to healthy controls (Leon et al. 
1977). This pioneering seminal work did not attract 
much interest until Stroun and colleagues (1989) 
showed that circulating DNA demonstrate similar 
properties such as decrease strand stability that were 
found in neoplastic cells. Subsequently, several proof 
of concept studies showed various tumour specific 
aberrations in the circulation such as mutation in 
oncogene and tumour suppressor gene (Sorenson et 
al. 1994; Silva et al. 1999b), microsatellite instability 
(Chen et al. 1996) and aberrant DNA methylation 
(Silva et al. 1999a). In recent years, studies are directed 
towards evaluating the clinical utility of ctDNA in the 
management of cancer (Takai et al. 2015).   
Origin of ctDNA 
ctDNA is the proportion of cell-free DNA (cfDNA) 
that originates from tumour cells and carry tumour-
specific alterations. They are short fragments of 
double stranded DNA that measures between 70 to 
200 base pairs but larger fragments of up to 21 
kilobases were also recorded (Jahr et al. 2001). The 
percentage of cfDNA that is derived from tumour 
varies from patient to patient, ranging from as low as 
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0.01% to a mutant allelic fraction as high as 93% (Jahr 
et al. 2001; Diehl et al. 2005; Forshew et al. 2012). It has 
been estimated that a patient with a tumour load of 
100g releases up to 3.3% of tumour-DNA into the 
circulation on a daily basis (Diehl et al. 2005). Despite 
numerous studies describing cfDNA, the mechanism 
of the origin of these circulating DNA in the blood 
remains ambiguous. Two possible, mutually non-
exclusive, mechanisms by which cfDNA enters into 
the circulation include passive release and active 
secretion (Figure 1). The passive release is mediated 
through the cellular destruction (both healthy and 
tumour cells) by apoptosis and necrosis (Jahr et al. 
2001). Additionally, cells may actively secrete DNA 
into the blood in the form of nucleoprotein complex 
(Stroun et al. 2001). A low proportion of cfDNA is also 
contributed by the lysis of circulating tumour cells 
that have been shed from the primary tumour (Stroun 
et al. 2000). 
Controversy exists in the literature regarding the 
contribution of necrosis and apoptosis in the origin of 
ctDNA. Some studies advocate that necrotic cells 
engulfed by the macrophages are the major source of 
ctDNA fragments (Diehl et al. 2005). However, recent 
studies have shown that these larger necrotic-derived 
DNA fragments were barely detectable in patients 
with pancreatic cancer (Sikora et al. 2015). 
Alternatively, many studies have suggested apoptosis 
as the main driver of release (reviewed in Vietsch et 
al. 2015). These observations were supported by the 
fact that ctDNA shows fragmentation pattern similar 
to nucleosomal DNA (~ 180 bp) (reviewed in Heitzer 
et al. (2015). Further studies are therefore required to 
elaborate the complex mechanism of origin of ctDNA 
and contribution of necrosis and apoptosis.   
Fig 1: Mechanisms of release of cfDNA from tumour cells. Cancer-
associated genetic alterations such as single nucleotide variants, 
copy number variations, methylation changes and chromosomal 
rearrangements can be detected in ctDNA 
Tumourgenic potential of ctDNA: The 
Genometastasis Hypothesis 
Interestingly, studies have shown that tumour-
derived circulating DNA might transfect susceptible 
cells in the distinct target organs resulting in 
metastases. This hypothesis was proposed by GarcÍA-
Olmo and GarcÍA-Olmo (2001) and have been 
supported by a number of experimental studies. A 
study by Garcia-Olmo et al. (2010) have demonstrated 
the potential of plasma DNA to transfect and 
oncogenically transform susceptible cells, and 
showed that plasma of colon cancer patient selectively 
transforms NIH/3T3 mouse cells while having no 
effect on human adipose-derived stem cells. Similar 
findings were also reported by Trejo-Becerril et al. 
(2012) in an in vivo immunocompetent colon-
carcinogenesis rat model. However, a number of 
observations have limited the validity of this 
hypothesis. In the studies cited above plasma was 
used as the source of ctDNA. Studies have shown that 
plasma also contains different types of cell-derived 
particles carrying nucleic acids, for example, exosome, 
apoptotic bodies and microvesicles (Belting and 
Wittrup 2008), and they have been shown to play an 
important role in tumorigenesis (Azmi et al. 2013; 
Martins et al. 2013). Therefore, the oncogenic 
transformations observed by authors could have been 
mediated by these extracellular cell-derived particles 
as opposed to cell-free nucleic acid. Moreover, the 
organ-specific tropism of metastases could not be 
explained by this hypothesis (Hunter et al. 2008).  
Kinetics of ctDNA 
Little is known about the elimination of circulating 
DNA from blood.  Studies on circulating foetal DNA 
from maternal plasma after delivery displays a half-
life between 4 and 30 minutes with an initial rapid 
phase followed by a slower phase of clearance (Lo et 
al. 1999). Different studies have speculated that the 
clearance is mainly mediated by liver, kidney, spleen 
and other physiological factors in blood such as 
plasma deoxyribonuclease (Botezatu et al. 2000; 
Minchin et al. 2001; Cherepanova et al. 2007). 
However, the contribution of these mechanisms in the 
clearance of ctDNA is still controversial. A study by 
Lo et al. (1999) showed that plasma nucleases plays a 
limited role in the clearance of circulating foetal DNA 
from maternal plasma. On the contrary, other studies  
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have identified leading contribution of plasma 
nucleases and showed that low DNase activity in the 
plasma of cancer patients resulted in the high level of 
circulating DNA (Tamkovich et al. 2006; Cherepanova 
et al. 2008).   
DETECTION OF ctDNA IN BLOOD 
Methodological aspects  
Two approaches are used to analyse circulating DNA 
as a biomarker for carcinogenesis: quantitative 
analysis of cfDNA and detection of tumour-specific 
alterations.   
Quantitative analysis of total cfDNA  
Studies have shown that the concentration of cfDNA 
is significantly higher in cancer patients compared to 
healthy controls owing to increased release from 
tumour cell turnover (Chang et al. 2002; Kamat et al. 
2010). Review of published articles by van der Vaart 
and Pretorius (2010) reported that yields of circulating 
DNA in the plasma of cancer patients were on average 
137 ng/ml, which is nine times greater than the 
concentration observed in the healthy individual 
(average 15 ng/ml).   
Various methods are available to purify circulating 
DNA from serum or plasma. The classic DNA 
isolation procedure is based on phenol-chloroform 
method, a liquid-liquid extraction method that form a 
biphasic emulsion with aqueous layer containing 
DNA and organic layer containing precipitated 
proteins (Sengüven et al. 2014). Other commercially 
available kits using silica based technology such as 
Purelink Genomic DNA extraction kit (Invitrogen), 
and magnetic separation such as Agencourt 
DNAdvance Kit (Beckman Coulter) are also available 
(as reviewed in Dhaliwal 2013). The isolated DNA is 
then quantified using different techniques, including 
DNA dipsticks (Invitrogen), nick translation, qPCR 
and fluorometry with SYBR green (Xue et al. 2006; van 
der Vaart and Pretorius 2010). 
Studies have demonstrated that quantitative analysis 
of cfDNA facilitates early detection of prostate, lung 
and breast cancer (Sozzi et al. 2003; Altimari et al. 
2008; Kohler et al. 2009). A study by Sozzi et al. (2003) 
has shown eight-fold increase in the concentration of 
cfDNA in lung cancer patient compared to controls. 
However, conflicting results were observed in 
different studies. In a study by Schmidt et al. (2008), 
no significant differences were observed in the 
amount of cfDNA in the tumour and non-tumour 
populations. Additionally, the concentration of 
cfDNA is also influenced by various physiological 
and pathological conditions such as pregnancy, 
exercise, heavy smoking, trauma, inflammatory 
diseases, premalignant conditions and chronic 
illnesses in elderly (reviewed in Fleischhacker and 
Schmidt 2007; Heitzer et al. 2015). Therefore, simple 
quantitative assessment has limited potential as a 
standalone biomarker, but it can be used as an adjunct 
with other conventional markers.  
Characterising tumour-specific alterations in circulating 
DNA 
Detecting tumour-specific genetic aberrations is a 
more sensitive and specific biomarker compared to 
the quantitative measurement of cfDNA (Jung et al. 
2010). These genetic alterations include point 
mutations, insertions and deletions, multi-nucleotide 
polymorphisms, loss of heterozygosity, microsatellite 
alterations, copy number variations, chromosomal 
rearrangements and epigenetic alterations (reviewed 
in Fleischhacker and Schmidt 2007; Chen et al. 2016) 
(Figure 1). 
Different technological platforms are available to 
detect these alterations. Broadly, they can be divided 
into two group i.e. targeted and untargeted 
approaches. The former includes the detection of 
known genetic changes in circulating DNA based on 
primary tumour genotype or analysing frequently 
occurring “driver” mutations in particular cancer. The 
untargeted approach includes techniques which do 
not require any prior knowledge of the mutation type. 
Techniques employed by different studies to detect 
ctDNA are summarised in Table 1. 
The targeted approach is mainly based on PCR-based 
assays. Earlier techniques employed for detecting 
known minority (mutant) alleles mainly focused on 
allele specific PCR-based assays (AS-PCR) also called 
amplification-refractory mutation system (ARMS) 
(Reviewed in Diaz and Bardelli 2014). Although this 
technique is comparatively inexpensive and does not 
require any specialised instruments, the results of AS-
PCR are semi-quantitative and provide only relative 
quantification to the control (Luke et al. 2014). This 
limitation has been overcome by combining ASPCR 
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with quantitative methods, for example, fluorescently 
labelled primer and probe (Taqman, scorpion-ARMS) 
and peptide nucleic acid (PNA) which have improved 
interpretation of PCR results (Board et al. 2008). Other 
modifications of PCR-based assays have also been 
reported such as co-amplification at lower 
denaturation temperature-PCR (COLD-PCR) and 
competitive allele-specific hydrolysis probes 
(TaqMan) PCR (CAST-PCR) (Table 1). Although AS-
PCR and its different technical modifications are 
sensitive in detecting mutant DNA, cross-reactivity 
has been observed between the probes. In a study by 
Didelot et al. (2012) using CAST-PCR, cross-reactivity 
was observed between mutant and wild-type probes 
for EGFR resistant mutation (T790M) and it impacted 
assay’s sensitivity.
 Table 1. Overview of selected techniques used for detection of ctDNA.  
Technique Sensitivitya Tumour 
type 
Gene assessed 
for mutations  
Selected studies using the 
technique  
Allele-specific 
PCR 
0.5% - 1% NSCLC 
 
Breast 
CRC 
EGFR 
 
PIK3CA 
KRAS, BRAF 
(Kimura et al. 2006; Maheswaran 
et al. 2008; Goto et al. 2012) 
(Board et al. 2010) 
(Spindler et al. 2012) 
Cold-PCR 0.01% - 0.1% NSCLC 
CRC 
EGFR 
KRAS, BRAF 
(Li et al. 2008) 
(Mancini et al. 2010) 
CAST-PCR 0.1–1 % Melanoma 
Ovarian 
BRAF 
Beta-globin 
(Ashida et al. 2016) 
(Kamat et al. 2010) 
PNA- PCR 0.1%–1% CRC 
Pancreatic 
KRAS 
KRAS 
(Xu et al. 2014) 
(Tjensvoll et al. 2016) 
Droplet-based 
digital PCR 
0.005% - 0.01% CRC 
Melanoma 
Breast 
NSCLC 
KRAS 
BRAF, NRAS 
PIK3CA 
EGFR 
(Taly et al. 2013) 
(Tsao et al. 2015) 
(Oshiro et al. 2015) 
(Zhu et al. 2015) 
BEAMing-Digital 
PCR 
0.01%–1.7% Breast 
NSCLC 
Melanoma 
PIK3CA 
EGFR 
BRAF, cKIT, 
NRAS, TERT 
(Higgins et al. 2012) 
(Thress et al. 2015) 
(Lipson et al. 2014) 
Whole genome 
sequencing 
1-5 % Prostate 
CRC 
 (Heitzer et al. 2013) 
(Diaz et al. 2013) 
Whole exome 
sequencing 
1% Breast, 
ovarian 
and lung 
 (Murtaza et al. 2013) 
TAm-Seq 2% Ovarian 
and Breast 
Breast 
Gene Panel 
 
PIK3CA, TP53 
(Forshew et al. 2012) 
 
(Dawson et al. 2013) 
Safe-SeqS  CRC KRAS, BRAF, 
TP53, SMAD4, 
PIK3CA, APC 
(Bettegowda et al. 2014) 
CAPP-Seq 0.02% NSCLC Gene panel (Newman et al. 2014) 
Ion-AmpliSeq 0.5% Breast Gene Panel (Rothe et al. 2014) 
 Estimated detectable fraction of mutated alleles (%) 
Abbreviations: BEAMing Digital PCR = Beads, Emulsions, Amplification and Magnetics; CAPP-Seq = Cancer personalized profiling by deep sequencing; 
CAST-PCR = Competitive allele-specific hydrolysis probes (TaqMan); CRC = colorectal carcinoma;  NSCLC = non-small cell lung cancer; PCR; COLD-
PCR = coamplification at lower denaturation temperature-PCR; PIK3CA = phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene; 
PNA-PCR = peptide-nucleic-acid-mediated-polymerase chain reaction clamping; Safe-SeqS = Safe-sequencing system; TAm-Seq = Tagged amplicon deep 
sequencing; TERT = Telomerase Reverse Transcriptase gene.
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Digital PCR (dPCR) based technologies effectively 
address limitations in earlier PCR based approaches. It 
separates the sample DNA molecules across a very 
large number of individual compartments such that 
each chamber has either one target temple or none. 
This technique was developed by Vogelstein and 
Kinzler (1999) and has been subsequently optimised 
using droplet-based (emulsion) or chip-based (nano-
fluidic) systems (Baker 2012). BEAMing PCR 
technology (Beads, Emulsions, Amplification, 
Magnetics) combines emulsion PCR with magnetic 
beads and flow-cytometry which enable highly 
sensitive mutational analysis and quantification of 
ctDNA (Diehl et al. 2006; Richardson and Iglehart 
2012). Studies have used dPCR based system to 
sensitively detect mutations in ctDNA at a very low 
allelic frequency (0.005% - 0.01%) in various tumour 
type (Table 1). However, dPCR is expensive, time 
consuming, require optimisation for each patient, and, 
like other targeted-based approaches described above, 
require prior knowledge of specific mutations to be 
analysed (reviewed in Luke et al. 2014).  
The untargeted approach using next generation 
sequencing (NGS) also known as massively parallel 
sequencing offer promising potential to identify 
genome-wide tumour-derived alterations in 
circulating DNA. NGS-based platforms have been 
used by different studies to perform whole genome 
and whole-exome analysis of circulating DNA, and 
capture known cancer gene panel (Table 1). However, 
there is a trade-off between increasing the portion of 
the genome to be sequenced and loss of coverage 
(depth) which limits the ability to detect the variant of 
low allelic fraction and differentiate it from a technical 
artefact (Gagan and Van Allen 2015).  Although 
genome-wide analysis of ctDNA (whole genome and 
exome sequencing) have promising applications, it is 
currently expensive and have lower analytical 
sensitivity (>1%) compared to dPCR-based 
approaches (Table 1) (Leary et al. 2012; Murtaza et al. 
2013; Ma et al. 2015).  
On the other hand, sequencing based on gene panel 
approach using hybrid capture (CAPP-Seq) or 
amplicon sequencing (TAm-Seq and Safe-SeqS) 
facilitate low-cost, high throughput and targeted deep 
sequencing of ctDNA (Forshew et al. 2012; Newman et 
al. 2014). In a study by Newman et al. (2014), cancer 
personalized profiling by deep Sequencing (CAPP-
Seq) was able to detect mutant allelic fraction as low as 
0.02% which highlights the high analytical sensitivity 
of gene panel-based NGS approaches. However, these 
techniques require advanced bioinformatics platform 
and are unable to detect translocation and 
rearrangements without prior knowledge of 
breakpoint information in case of amplicon-based 
sequencing (Bratman et al. 2015; Gagan and Van Allen 
2015).  
Technical aspects 
ctDNA is a technically challenging analyte owing to 
lower concentration of tumour-specific DNA within 
the background of cfDNA derived from non-tumorous 
cells. Pre-analytical and analytical issues related to 
ctDNA measurement hinders consistency and 
reliability of the results obtained. Studies have shown 
that concentration of cfDNA is affected by various pre-
analytical factors related to blood sampling and 
processing such as use of different anticoagulants for 
sample collection, time interval between sample 
collection and processing, centrifugation conditions 
and whether serum or plasma is used for ctDNA 
analysis (reviewed in Jung et al. 2010). The use of 
serum or plasma as an optimal sampling specimen is 
controversial (Schwarzenbach et al. 2011). Although 
the amount of circulating DNA in serum is about 3 to 
24 fold higher than those found in plasma (Jung et al. 
2003), it is considered a less suitable material because 
of DNA contamination from leukocyte during the 
clotting process (Lee et al. 2001). However, a study by 
Umetani et al. (2006) showed that increased 
concentration of circulating DNA observed in serum 
might not be due to extraneous DNA contamination 
and could occur due to unequal distribution of 
tumour-related cfDNA during serum separation from 
whole blood. Nonetheless, plasma should be preferred 
over the serum as a sampling specimen to obtain 
reliable results due to a lower level of background wild 
type extraneous DNA.  Different studies have also 
made similar recommendation (Park et al. 2012; 
Heitzer et al. 2015). Standardisation and 
methodological harmonisation of pre-analytical 
variables are important to achieve reliable, consistent 
and comparative results.   
Analysis of ctDNA using different assay platforms and 
DNA isolation techniques are also responsible for the 
inconsistencies in the results obtained by various 
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studies. As demonstrated in Table 1, analytical 
approaches and assay sensitivity varies between 
different platforms. A recent study by Thress et al. 
(2015) compared the ability of different technological 
platforms to detect EGFR mutation (T790M) from 
ctDNA. The study has showed that digital PCR-based 
methods (droplet digital-PCR and BEAMing digital-
PCR) were purportedly more sensitive than non-
digital platforms (ARMS) for detection of mutant 
sequences. Additionally, as reviewed by Jung et al. 
(2010), a large number of alternative protocols for 
DNA isolation is also responsible for variability in 
circulating DNA concentration observed by different 
studies. Therefore, it is imperative to develop 
consensus on reliable and efficient methods to achieve 
standardisation.       
CLINICAL IMPLEMENTATION OF ctDNA 
ctDNA has emerged as a promising biomarker with 
various potential applications in precision oncology. 
Applicability of ctDNA as a diagnostic biomarker 
Analysis of tumour-specific mutations as a diagnostic 
biomarker have been demonstrated by different 
studies (Table 2). Detection of corresponding mutations 
in various genes including Kirsten Rat Sarcoma Viral 
Oncogene Homolog (KRAS), Tumor Protein P53 
(TP53) and Adenomatous Polyposis Coli (APC) have 
been found in patients with pancreatic carcinoma 
(Kinugasa et al. 2015), colorectal cancer (Tie et al. 2015) 
and ovarian cancer (Forshew et al. 2012), to name a few 
(See Table 2 for selected studies assessing ctDNA in 
different tumour type). In an exemplary paper, 
Bettegowda et al. (2014) have demonstrated the ability 
of ctDNA to detect the tumour in a large cohort of 
patients with different tumour type. They have shown 
that detectable levels of ctDNA were found in 49% to 
78% of patients with localised tumours. However, as 
indicated in the same study, patient with stage 1 cancer 
and neoplasm of CNS (e.g. Glioma) showed a very low 
level of ctDNA. Moreover, Trombino et al. (2005) 
found no concordance between KRAS mutations 
found in circulating DNA and tumour tissue from 
patients with NSCLC. Ramirez et al. (2003), on the 
other hand, found more mutations in KRAS gene in the 
serum of patient compared to the primary NSCLC. 
These contradictory findings question the validity of 
tumour-specific mutations as a diagnostic biomarker.  
Another approach to facilitate cancer diagnostics using 
ctDNA is detection of epigenetic alterations 
particularly methylation changes in the circulating 
DNA. Aberrant DNA methylation in the numerous 
gene such as APC, Glutathione S-Transferase Pi 1 
(GSTP1), Cyclin-Dependent Kinase Inhibitor 2A 
(CDKN2A), p16, SEPT9, O-6-Methylguanine-DNA 
Methyltransferase (MGMT), Retinoic Acid Receptor 
Beta (RARβ2) and Ras Association Domain Family 
Member 1A (RASSF1A) have been analysed in cfDNA 
extracts (reviewed in Jung et al. 2010; Schwarzenbach 
et al. 2011). The diagnostic sensitivity of methylation 
markers in different cancers varies from 2% to 75% 
using a single methylation marker (Jung et al. 2010). 
Combining methylation markers remarkably 
improves the diagnostic sensitivity. As shown in a 
study by Skvortsova et al. (2006), combining 
methylation markers RARβ2 and RASSF1A provide 
95% diagnostic coverage (sensitivity) for detection of 
breast cancer. However, Fujiwara et al. (2005), 
reported cases where no concordance was observed 
between circulating DNA methylation and 
corresponding tumour tissue. The authors have 
speculated that it might be due to undetected pre-
cancerous lesions or caused by environmental factors 
such as smoking. Additionally, the altered methylation 
patterns in circulating DNA are also age-dependent 
(Fleischhacker and Schmidt 2007). Therefore, these 
factors should be taken into account before using 
methylation status as a tumour-specific biomarker.   
Applicability of ctDNA as a prognostic biomarker 
Stratification of cancer patients based on clinical 
prognosis is very important to precisely tailor the 
treatment according to the need of individual patients. 
In this regard, ctDNA plays a very important role to 
stage cancer, monitor tumour burden, predict survival 
and detect disease recurrence.  
Molecular staging of the tumour is one of the reliable 
predictors of prognosis (Eschrich et al. 2005). Studies 
have shown a significant correlation between disease 
stage and the level of tumour-associated genetic 
alterations found in the circulation (reviewed in 
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Crowley et al. 2013). A study by Diehl et al. (2005) 
conclusively demonstrated that the fraction of mutant 
molecules (APC) found in the plasma of patients with 
CRC were significantly associated with tumour stage. 
A recent study by Bettegowda et al. (2014) also 
supports this conclusion and showed that the 
concentration of ctDNA in the plasma increases with 
tumour stage across various tumour type. They found 
that the fraction of patients with detectable ctDNA was 
47, 55, 69, and 82% in stage I, II, III, and IV cancers, 
respectively. However, conflicting results were 
obtained by some earlier studies in patients with 
pancreatic and CRC, showing no correlation between 
KRAS gene mutations in circulating DNA and 
clinicopathological parameters including tumour 
stage (Yamada et al. 1998; Frattini et al. 2008). 
Controversies associated with these studies might be 
due to the limited sample size and selection of 
appropriate patient cohort, for example, in the above-
mentioned study by Frattini et al. (2008), there was 
considerable variability in certain demographics 
characteristics of patients such as tumour size and 
tumour-grade (moderate or poor). 
Although ctDNA shows a great promise in staging 
tumour as described above, it might not be superior to 
current clinical methods (radiology, histopathology 
and clinical observation) to stage a tumour. As the 
concentration of ctDNA depends on the cellular 
turnover which increase with the volume of the 
tumour (Schwarzenbach et al. 2011), it might not be 
effective to stage early-cancer when the tumour 
volume is significantly low.  
On the other, ctDNA has emerged as a superior 
biomarker to predict survival, determine the risk of 
recurrence and detect minimal residual disease. As 
shown in Table 2, different studies have demonstrated 
the remarkable potential of ctDNA to determine 
prognosis in breast, lung, CRC and ovarian cancer. 
Especially in the setting of advance-stage, non-
resectable tumour, ctDNA offers an effective 
alternative to identify tumour-specific mutations in 
plasma that hold prognostic and predictive 
information. In a study by Nygaard et al. (2013), KRAS 
mutations in plasma were found to be an independent 
prognostic marker in patients with NSCLC. The 
authors have suggested that the detection of plasma 
mutated KRAS could serve as an alternative to 
invasive tissue biopsy in establishing prognosis in 
these patients. However earlier study by Camps et al. 
(2011) using the same technique (qPCR) to detect 
plasma mutated KRAS showed no significant 
relationship with overall survival and progression-free 
survival in patients with advance-stage NSCLC. The 
opposing outcome between these two studies might be 
due to methodological differences. Both of these used 
qPCR to detect mutation, but the earlier study by 
Camps et al. (2011) targeted only two KRAS mutations 
in codon 12, while the later study interrogated six 
KRAS mutations in codon 12 thus resulting in 
increased detection of plasma mutated KRAS (17.5% 
compared to 8.8% in earlier study). However, the 
prognostic value and clinical utility of ctDNA in the 
context of a resectable tumour is very limited. Since the 
tumour sample is itself available, conventional tests 
such as histology, immunohistochemistry and 
molecular analysis can be performed to determine 
prognosis (Crowley et al. 2013).   
Early identification of disease recurrence is important 
to stratify patients, so that aggressive and 
multidisciplinary approaches could be adopted in 
patients with a limited disease which might improve 
disease control and offer survival benefit (Pagani et al. 
2010). In this regard, ctDNA has proved to be a useful, 
minimally invasive biomarker in setting of adjuvant 
therapy. In a recent study by Olsson et al. (2015), the 
eventual clinically detected recurrence (metastasis) 
was accurately determined by serial monitoring of 
ctDNA in patients with primary breast cancer who 
underwent potentially curative surgery. The study 
also showed that in 86% of the patients, ctDNA-based 
detection of occult metastasis preceded the clinical 
diagnosis with a mean lead time of 11 months. 
However, the current study was limited by small 
sample size (20 patients) and retrospective study 
design. Other studies have also highlighted the role of 
ctDNA as a predictor of poor outcome and showed a 
consistent relationship between disease recurrence 
and reappearance of tumour-specific aberrations in 
circulating DNA in various cancer type (Diehl et al. 
2008; Kuhlmann et al. 2012; Kinugasa et al. 2015), also 
see Table 2. Moreover, studies have shown that the 
ability of ctDNA to predict recurrence were superior to 
standard biomarker (CEA) (Diehl et al. 2008; Sato et al. 
2016).   
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Table 2. Selected studies of ctDNA detection in various tumour types. 
Tumour type Patients 
number 
Genetic alterations  Source Analytical 
Platform 
Clinical Utility Reference 
Colorectal 
Cancer 
18 Mutations APC, APC, 
KRAS, PIK3CA, TP53 
Plasma BEAMing  
Digital PCR 
Prognostic (Tumour 
burden) 
(Diehl et al. 
2008) 
  53 Mutations in panel of 
15 genes 
Plasma Safe-SeqS Prognostic (Tumour 
response) 
(Tie et al. 2015) 
  64 Mutations in KRAS, 
BRAF, TP53, SMAD4, 
PIK3CA, APC 
Plasma Safe-SeqS Diagnostic, 
Prognostic (Tracking 
resistance) 
(Bettegowda et 
al. 2014) 
  29 Mutations in KRAS, 
Methylation RASSF2A 
promoter 
Serum PCR, MS-
PCR 
Prognostic (Clinical 
outcome) 
(Lefebure et al. 
2010) 
Breast Cancer 30 Mutations in PIK3CA, 
TP53, and Structural 
variation 
Plasma TAm-Seq 
and digital 
PCR 
Prognostic (Tumour 
burden) 
(Dawson et al. 
2013) 
 20 Chromosomal 
rearrangements 
Plasma droplet 
digital PCR 
Prognostic (Poor 
outcome, eventual 
clinical recurrence)  
(Olsson et al. 
2015) 
 171 Mutations in ESR1 Plasma Digital PCR Predictive (Predict for 
resistance to 
Aromatase 
inhibitors therapy) 
(Schiavon et al. 
2015) 
 72 Mutations in PIK3CA   Plasma and 
Serum 
ARMS-
Scorpion, 
PCR 
Predictive (Predict 
response to PI3K 
inhibitor)  
(Board et al. 
2010) 
Non-small-cell 
lung cancer 
246 Mutations in KRAS Plasma ARMS-
qPCR 
Prognostic  (poor 
outcome) 
(Nygaard et al. 
2013) 
  803 Mutations in EGFR Plasma Allele-
specific 
PCR 
Predictive (predict 
response to Gefitinib 
treatment) 
(Douillard et al. 
2014) 
  13 Multiple somatic 
mutations and fusions  
Plasma CAPP-Seq Diagnostic and 
Prognostic  
(Newman et al. 
2014) 
Ovarian cancer 38 Mutations in TP53, 
PTEN, EGFR, BRAF, 
KRAS 
Plasma TAm-Seq, 
digital PCR 
Prognostic (metastatic 
relapse) 
(Forshew et al. 
2012) 
 137 Mutations in TP53  Plasma/serum PCR Prognostic (Reduced 
Survival)  
(Swisher et al. 
2005) 
Pancreatic 
cancer 
121 Mutations in KRAS Plasma Safe-SeqS Diagnostic and 
Prognostic 
(Bettegowda et 
al. 2014) 
  75 Mutations in KRAS Serum Droplet 
digital PCR 
Diagnostic and 
Prognostic 
(Predicting survival) 
(Kinugasa et al. 
2015) 
  14 Mutations in KRAS Plasma PNA-PCR Prognostic (predict 
survival)  
(Tjensvoll et al. 
2016) 
Oesophageal 
cancer 
39 Promoter 
hypermethylation in 
TP53 
Serum MS-PCR Diagnostic (screening 
patients)  
(Hibi et al. 2001) 
Hepatocellular 
carcinoma 
26 Hypomethylation and 
copy number 
aberrations 
Plasma Bisulfite 
sequencing 
(WGS) 
Diagnostic and 
Prognostic 
(Chan et al. 
2013) 
Oral 
squamous-cell 
carcinoma 
20 Microsatellite loci Serum PCR Prognostic (Kakimoto et al. 
2008) 
Abbreviations: ARMS-PCR = Amplification-refractory mutation system; BEAMing Digital PCR = Beads, Emulsions, Amplification and Magnetics; CAPP-
Seq = Cancer personalized profiling by deep sequencing; ESR1 = Estrogen Receptor 1; MS-PCR = Methylation specific PCR; PNA-PCR = peptide-nucleic-
acid-mediated-polymerase chain reaction clamping; PTEN = Phosphatase and Tensin Homolog; Safe-SeqS = Safe-sequencing system; TAm-Seq = Tagged 
amplicon deep sequencing; WGS = Whole Genome Sequencing
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ctDNA is also superior to radiological studies in 
detecting disease recurrence. A recent study by Tie et 
al. (2015) showed that early changes in ctDNA in CRC 
patients receiving chemotherapy predict later 
radiological response. The resolution limit of 
radiological imaging studies to detect tumour is a 
tumour-size of approx. 7–10 mm which contain about 
1 billion cells (Francis and Stein 2015). In comparison, 
tumour containing about 50 million malignant cells 
releases sufficient DNA which can be detected in 
circulation (Diaz et al. 2012). Monitoring tumour 
progression and recurrence requires selection of 
suitable mutations which are present from the 
initiation of tumourigenesis and is less responsive to 
therapeutic interventions (Crowley et al. 2013). 
However, selection of these candidate mutations is 
not a simple task because as cancer evolve, it acquires 
a plethora of somatic mutations (Bardelli et al. 2003), 
and therefore, detailed knowledge of different key 
mutations in different cancers is required. 
Multiplexed mutation detection across a panel of gene 
holds better clinical utility as a compared to detecting 
frequently mutated gene (Kidess et al. 2015).   
Applicability of ctDNA as a predictive biomarker 
The presence or absence of actionable oncogenic 
mutations in the archived tumour tissue sample is 
currently being used to guide clinical management 
using a number of available targeted therapies such as 
gefitinib, cetuximab, everolimus etc. (reviewed in Tu 
et al. 2016). As described above, archived tissue 
specimen does not effectively reflect the genomic 
landscape of a tumour. These genetic alterations have 
also been determined in ctDNA which suggests that it 
could be used as a viable alternative to invasive tissue 
analysis. In an elegant study by Thierry et al. (2014), 
authors have compared KRAS and BMRAF mutations 
in tumour tissue obtained by routine methods and 
plasma DNA and demonstrated a very high 
concordance (96%) between these two methods. 
Spindler et al. (2012) showed that quantitative 
analysis of plasma mutated KRAS helps in 
stratification of patients with metastatic CRC, and 
identify patients who could potentially benefit from 
anti-EGFR therapy.  
ctDNA analysis has also emerged as a tool for 
monitoring therapeutic response and early detection 
of acquired resistance (Table 2). In a study by Gray et 
al. (2015), the plasma concentration of BRAF and 
NRAS mutations in patients with advanced metastatic 
melanoma were found to be associated with treatment 
response. Likewise, a study by Dawson et al. (2013) 
showed that the trend of serial ctDNA levels 
correlated with radiologic response to therapy in 
patients with metastatic breast cancer. These studies 
highlighted the potential of ctDNA analysis in 
monitoring tumour dynamics following treatment. 
Additionally, ctDNA analysis has been used to detect 
resistance-associated mutations which were 
previously detected by tumour re-biopsy using 
invasive clinical procedures. In a study by Zheng et al. 
(2016), EGFR T790M mutation which is associated 
with acquired resistance to TKI therapy in patients 
with NSCLC has been demonstrated in ctDNA and 
has shown to be a minimially invasive alternative to 
guide clinical management in these patients.   
CONCLUSIONS 
ctDNA has emerged as a minimally invasive 
substitute to traditional tumour tissue biopsy. 
Growing evidence have highlighted the promising 
role of ctDNA as a prognostic and predictive 
biomarker and demonstrated that it could be used as 
a surrogate for tumour tissue to predict the outcome, 
monitor tumour burden, detect recurrence, and 
identify genetic determinants for therapy. However, 
despite great potential of this technique, it has not 
been approved for routine clinical use.  
Many hurdles should be overcome before ctDNA 
analysis can be adopted into routine clinical practices. 
One of the major challenges is the lack of 
standardisation in technical approaches. 
Inconsistencies are observed in preferable sample 
type (plasma or serum), sample processing and 
techniques employed for genotyping ctDNA. 
Therefore, methodological harmonisation, 
standardisation and consensus on technical 
approaches are required to achieve reliable, consistent 
and comparative results. Another major challenge is 
related to the specificity of molecular alterations. 
Individual tumour-derived mutations are never 100% 
specific for particular cancer and significant overlap 
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has been observed in different cancers. Thus, ctDNA 
analysis using a single gene-marker is of limited value 
and might lead to false-positive results. On this 
account, ctDNA analysis using a multi-gene panel 
may increase the test specificity. Additionally, 
although promising results have been shown by 
different proof-of-concept studies, prospective, well-
designed and adequately powered validation studies 
in a large cohort and multiple tumour types are 
required to establish the clinical validity and utility of 
ctDNA analysis. 
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